BIIB
NASDAQ · Healthcare · Drug Manufacturers - General · US
Research · Oct 29, 2026
Biogen (BIIB) Q3 2026 Earnings: Apellis Dilution Cut to About $0.55
Biogen Q3 2026 revenue rose 10.6% as Apellis cut expected 2026 EPS dilution to about $0.55 and SPINRAZA high-dose conversion beat plan, though both include one-time gains.
Research · Oct 24, 2026
[BIIB] Biogen: Q3 2026 Earnings Test Whether Growth Products Can Outrun MS Erosion
Biogen's Q2 2026 revenue rose 3% to $2.74B as growth products hit $1.06B, overtaking legacy MS; Q3 tests whether high-dose SPINRAZA and SYFOVRE gains hold.
Research · Sep 3, 2026
[BIIB] Biogen Thesis 2026: New Growth Portfolio Offsets Accelerating Multiple Sclerosis Decline
Biogen FY25 revenue $9.81B (+1%); op income $1.88B (-25%); NI $1.29B (-21%); EPS $8.83. Growth products $3.3B (+19% YoY) — flagship inflection: LEQEMBI + SKYCLARYS + ZURZUVAE + QALSODY each >$1B cumulative since launch. LEQEMBI 60% anti-amyloid market share. SKYCLARYS Q4 $133M (+30%); 34 markets globally. ZURZUVAE doubled FY25 sales. SPINRAZA Q4 $356M. VUMERITY Q4 $181M. MS franchise $3B but declining (TECFIDERA generic erosion EU; TYSABRI biosimilar pressure). FY26 guide: revenue mid-single-digit decline; non-GAAP EPS $15.25-$16.25; gross margin consistent; OpEx consistent.
Research · Aug 25, 2026
Rare-Disease Gene Therapy Shifts From Sham-Surgery Control to Delivery Hardware and Endpoint Instruments
The FDA told uniQure a sham-surgery control is no longer required, moving the cost of rare-disease gene therapy onto delivery hardware and endpoint instruments.